Researchers Identified New Genetic Risk Test for Preeclampsia

A newly discovered seven-gene signature could help clinicians better predict pregnancy risks.

Updated on Sept. 24, 2026 in Pregnancy

Isometric editorial illustration featuring a seven-part geometric protein chain next to a monolithic plinth, representing a new genetic risk stratification tool. — Researchers have identified a seven-gene signature capable of stratifying preeclampsia risk, achieving an area under the curve of 0.893 in recent genetic testing. AI Illustration. Upload story photo >

Scientists have identified a specific seven-gene signature that can assist in stratifying the risk of preeclampsia. The diagnostic model reached an area under the curve (AUC) of 0.893 in recent testing.

Why it matters

Understanding placental transcriptomic changes may lead to more accurate risk assessments for expectant parents. This research helps clarify the biological pathways that contribute to preeclampsia during pregnancy.

The seven genes identified are ACOXL, FADS2, HPGD, CPOX, LDHA, BMPR1B, and GAPDHS. The model showed strong performance with an AUC of 0.893 in initial discrimination tests.

The players

Nature

A leading international scientific journal that publishes high-impact peer-reviewed research.

The details

Researchers integrated four existing genomic datasets and applied machine learning techniques, including LASSO regression and SVM algorithms, to isolate the gene signature. Five of the identified genes were found to be elevated in high-risk groups associated with hypoxia and extracellular matrix adhesion. A nomogram was constructed to translate these transcriptomic findings into a usable risk stratification tool.

September 24, 2026: The research findings were formally published.

Pregnancy
Sept. 24
Researchers Mapped Immune Changes in Mouse Placentas
Pregnancy
Sept. 23
RNA Preeclampsia Drug Trial Has Commenced
Aquariums
Sept. 22
New Sonar Dataset Released for Reef Mapping

The Home Front

This development follows a long-standing trend of using transcriptomic sequencing to better understand complex pregnancy complications like preeclampsia. It builds on established molecular research aimed at refining prenatal diagnostic capabilities.

This research is currently in the experimental stage and is not yet a diagnostic test you can request at a doctor's office. Keep these scientific updates in mind as you discuss your prenatal care plan and health history with your obstetrician or medical provider.

The takeaway

Advancements in gene signature identification are improving the precision of pregnancy risk assessment. Patients should continue to prioritize regular prenatal checkups and consult with specialists regarding personalized screening options for high-risk pregnancies.